Welcome to our dedicated page for Petvivo Holdings news (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on Petvivo Holdings stock.
Petvivo Holdings, Inc. (PETVW) is a pioneer in developing innovative biomedical devices for companion animals, leveraging human medical advancements to address veterinary health challenges. This dedicated news hub provides investors and industry professionals with essential updates on the company's progress in pet therapeutics.
Access real-time announcements covering regulatory milestones, product developments, and strategic partnerships. Our curated collection includes earnings reports, technology licensing updates, and clinical trial progress related to PETVW's portfolio of joint care solutions like the Spryng™ OsteoCushion™ system.
Key updates focus on commercialization efforts for veterinary medical devices, intellectual property expansions, and market penetration strategies. Stay informed about PETVW's unique approach to adapting human biomaterials for animal health applications through this comprehensive news resource.
Bookmark this page for direct access to verified company communications and third-party analysis. Check regularly for developments in PETVW's mission to enhance animal mobility through advanced therapeutic solutions.
PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) reported significant financial results for Q3 of fiscal 2023, highlighting revenues of $510,109, a substantial increase from $51,004 in Q3 2022. This growth is attributed to the commercialization of its product, Spryng™ with OsteoCushion™ Technology, with $456,502 stemming from shipments to distributor MWI Animal Health. Despite increased revenues, the company's net loss for the quarter rose to $2,311,618 or ($0.23) per share, compared to ($0.17) per share last year, driven by increased operating expenses totaling $2,605,240.
PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW) will report its financial results on February 9, 2023, after market close. A conference call is scheduled for 4:00 p.m. CT (5:00 p.m. ET) to discuss these results. Investors can access the live webcast through the company's Investor Relations website.
PetVivo focuses on innovative medical therapeutics for animals, with a product pipeline of seventeen offerings and nineteen patents protecting its technologies. The lead product, SPRYNG™ with OsteoCushion™ technology, targets joint-related afflictions in dogs and horses.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) is set to exhibit its innovative product, Spryng with OsteoCushion Technology, at the Minnesota Veterinary Medical Association Annual Meeting from February 2-4, 2023, in Minneapolis. Spryng is designed to manage lameness and joint issues like osteoarthritis in companion animals through an injectable veterinary medical device made from natural components. The company aims to leverage human therapies for animal treatment, showcasing a robust pipeline protected by nineteen patents. CEO John Lai invites attendees to visit their booth for insights on this veterinary advancement.
PetVivo Holdings, focused on companion animal health, will participate in the virtual Lytham Partners Investor Select Conference on January 31, 2023. CEO John Lai will present the company's innovative product, Spryng with OsteoCushion Technology, which is designed to manage joint issues like osteoarthritis in pets through an injectable delivery system. The conference will also include one-on-one meetings with management for investors. PetVivo has developed a range of biomedical devices and holds 19 patents to protect its technology. The company aims to accelerate the commercialization of its veterinary products, which are available for sale.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has announced its participation in the 2023 Lake Tahoe Equine Conference from January 23-27, 2023, held at Hyatt Lake Tahoe, Nevada. The company aims to showcase its innovative product, Spryng™ with OsteoCushion™ Technology, which is designed to manage lameness and joint issues in companion animals. This injectable veterinary medical device combines extracellular matrix particles to support damaged cartilage and address tissue defects. PetVivo's strategy focuses on leveraging human therapies for animal treatments, accelerating revenue timelines, and capitalizing on a portfolio of nineteen patents to protect its innovative biomaterials and methods.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will showcase its innovative veterinary medical device, Spryng™, at the 2023 FAEP Ocala Equine Conference on January 21-22, 2023, in Ocala, FL. The company aims to network with equine industry leaders to enhance its OsteoCushion™ Technology, which supports joint health in companion animals, particularly for osteoarthritis treatment. Spryng™ utilizes an injectable formulation of micronized extracellular matrix particles to assist in managing lameness and joint issues. PetVivo's strategy involves leveraging human medical innovations for quicker veterinary solutions.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced a lease for 14,000 sq. ft. in Edina, Minnesota, to expand its production capacity for Spryng™ with OsteoCushion™ Technology and other medical devices. This facility will feature clean rooms for large-scale production, slated to begin in August 2023. CEO John Lai emphasized this expansion aims to meet global demand for Spryng™, a veterinary device addressing lameness in animals. The company holds nineteen patents for its products, reinforcing its commitment to innovative veterinary medical solutions.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced its participation in the Veterinary Meeting & Expo, occurring from January 14-18, 2023, in Orlando, FL. The company will showcase its lead product, Spryng™ with OsteoCushion™ Technology, designed for managing joint afflictions in companion animals. This conference is the largest veterinary event in the U.S., attracting over 10,000 attendees. CEO John Lai expressed enthusiasm for networking with industry leaders to advance the commercialization of veterinary medical devices.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced its application for a dual listing on Upstream, a trading app for digital securities and NFTs. This initiative aims to provide access to a global investor base using USDC digital currency, credit, debit, PayPal, and USD. CEO John Lai emphasized enhancing liquidity and value for shareholders. Approval by MERJ is necessary, but as a Nasdaq issuer, an expedited listing process may be available. PetVivo specializes in biomedical devices for companion animals, with a focus on innovative therapies.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will present at the Sequire Virtual Small Cap Conference on December 8, 2022, at 2:30 PM EST. CEO John Lai will showcase Spryng™ with OsteoCushion™ Technology, a veterinary device designed for managing lameness and joint issues like osteoarthritis in companion animals. This product offers a natural solution with micronized extracellular matrices that reinforce cartilage support and address tissue defects. The event aims to connect small-cap investors with innovative companies in the biomedical space.
FAQ
What is the current stock price of Petvivo Holdings (PETVW)?
